Piramal Pharma to acquire remaining 26% stake in Yapan Bio
With the acquisition, Piramal will fully embed Yapan’s advanced large molecule capabilities into its integrated service offering
More news in Industry
Cyient Semiconductors secures $10 million strategic investment from GlobalFoundries
Three bank unions call for strike on December 3
ACME seals $3.6-billion deal for Odisha green ammonia project
Apollo Micro, Redon ink MoU to collaborate for tethered drone systems